Efficacy and safety of endocrine monotherapy as first-line treatment for hormone-sensitive advanced breast cancer: A network meta-analysis

BACKGROUND: Endocrine therapy was recommended as the preferred first-line treatment for hormone receptor-positive (HR+, i.e., ER+ and/or PgR+), human epidermal growth factor receptor-2-negative (HER2−) postmenopausal advanced breast cancer (ABC), but which endocrine monotherapy is optimal lacks cons...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Jingwen, Huang, Yanhong, Wang, Changyi, He, Yuanfang, Zheng, Shukai, Wu, Kusheng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2017
Materias:
5750
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5571723/
https://www.ncbi.nlm.nih.gov/pubmed/28816986
http://dx.doi.org/10.1097/MD.0000000000007846

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5571723/
https://www.ncbi.nlm.nih.gov/pubmed/28816986
http://dx.doi.org/10.1097/MD.0000000000007846

Ejemplares similares